Peregrine Capital Management LLC lifted its stake in Lantheus Holdings Inc (NASDAQ:LNTH) by 1.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 431,077 shares of the medical equipment provider’s stock after buying an additional 6,122 shares during the quarter. Peregrine Capital Management LLC’s holdings in Lantheus were worth $6,164,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its holdings in shares of Lantheus by 49.2% in the second quarter. Pacer Advisors Inc. now owns 8,036 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 2,651 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Lantheus by 49.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,135 shares of the medical equipment provider’s stock worth $73,000 after buying an additional 1,697 shares in the last quarter. James Investment Research Inc. lifted its holdings in shares of Lantheus by 8.3% in the second quarter. James Investment Research Inc. now owns 33,645 shares of the medical equipment provider’s stock worth $481,000 after buying an additional 2,565 shares in the last quarter. Denali Advisors LLC purchased a new position in shares of Lantheus in the second quarter worth $341,000. Finally, Creative Planning lifted its holdings in shares of Lantheus by 3.8% in the second quarter. Creative Planning now owns 18,749 shares of the medical equipment provider’s stock worth $268,000 after buying an additional 682 shares in the last quarter. 98.18% of the stock is currently owned by hedge funds and other institutional investors.
Shares of LNTH opened at $13.48 on Friday. The company’s fifty day moving average is $14.59 and its 200 day moving average is $14.48. Lantheus Holdings Inc has a fifty-two week low of $8.67 and a fifty-two week high of $27.12. The stock has a market capitalization of $535.91 million, a PE ratio of 44.93 and a beta of 1.26. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.41 and a current ratio of 2.37.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, July 30th. The medical equipment provider reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.08. Lantheus had a net margin of 3.51% and a return on equity of 20.57%. The company had revenue of $66.01 million for the quarter, compared to analysts’ expectations of $55.77 million. During the same quarter in the previous year, the business posted $0.27 earnings per share. Lantheus’s quarterly revenue was down 23.0% on a year-over-year basis. As a group, research analysts forecast that Lantheus Holdings Inc will post 0.18 earnings per share for the current year.
Several equities analysts have recently commented on the stock. Jefferies Financial Group began coverage on shares of Lantheus in a report on Monday, June 29th. They issued a “buy” rating and a $29.00 target price on the stock. BidaskClub upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a research report on Tuesday, June 23rd. CJS Securities upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 16th. Finally, Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a research report on Friday, July 10th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $29.00.
In other Lantheus news, insider John J. Bolla sold 2,422 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $14.29, for a total transaction of $34,610.38. Following the transaction, the insider now owns 60,419 shares in the company, valued at $863,387.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mary Anne Heino sold 3,000 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $16.02, for a total transaction of $48,060.00. Following the transaction, the chief executive officer now owns 604,793 shares in the company, valued at approximately $9,688,783.86. The disclosure for this sale can be found here. Insiders have sold 27,547 shares of company stock worth $436,892 in the last quarter. Company insiders own 2.08% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Featured Article: The basics of gap trading strategies
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.